GTS Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

GTS Securities’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,845	Closed	-$183K	–	4111
2024 Q2	$183K	Buy	+11,845	New	+$184K	﹤0.01%	3479

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GTS Securities's CPRX Position: Q3 2024 in Review

GTS Securities sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 11,845 shares — an estimated $183K sold.

GTS Securities first reported a position in CPRX in Q2 2024 and held it in 1 quarter. The position peaked at $183K in Q2 2024. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

GTS Securities reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
GTS Securities sold 11,845 Catalyst Pharmaceutical shares in Q3 2024, an estimated $183K.
GTS Securities first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 1 quarter.
GTS Securities's Catalyst Pharmaceutical position peaked at $183K in Q2 2024.
316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.